<DOC>
	<DOCNO>NCT00000781</DOCNO>
	<brief_summary>To determine relative clinical efficacy zidovudine ( AZT ) plus didanosine ( ddI ) , AZT plus zalcitabine ( ddC ) , AZT alternate monthly ddI , AZT/ddI plus nevirapine HIV-infected patient advanced disease . The rapid emergence resistant HIV strain observe patient receive monotherapy nucleoside analog non-nucleoside reverse transcriptase inhibitor . Use combination therapy two nucleoside drug convergent combination therapy two nucleoside non-nucleoside RT inhibitor may minimize evolution resistant HIV strain . Since toxicity major problem patient advance disease receive combination nucleoside therapy , alternate two drug may provide way retain several benefit combination therapy minimize increased toxicity .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Four-Arm Study Comparing Combination Nucleoside , Alternating Nucleoside , Triple-Drug Therapy Treatment Advanced HIV Disease ( CD4 &lt; = 50/mm3 )</brief_title>
	<detailed_description>The rapid emergence resistant HIV strain observe patient receive monotherapy nucleoside analog non-nucleoside reverse transcriptase inhibitor . Use combination therapy two nucleoside drug convergent combination therapy two nucleoside non-nucleoside RT inhibitor may minimize evolution resistant HIV strain . Since toxicity major problem patient advance disease receive combination nucleoside therapy , alternate two drug may provide way retain several benefit combination therapy minimize increased toxicity . Patients randomize receive either AZT/ddC , AZT/ddI , AZT alternate monthly ddI , AZT/ddI/nevirapine . Patients evaluate week 0 every 4 week thereafter 2 year . Pharmacologic , virologic , macroneurologic substudies conduct . Patients already enrol protocol ACTG 193 give option continue originally assign ACTG 193 therapy additional 6 month undergo re-randomization one four treatment arm ACTG 193A .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis . Allowed : Erythropoietin maintenance . GCSF GMCSF . Prophylaxis Mycobacterium avium intracellulare . Antifungal prophylaxis treatment specific drug . Maintenance therapy opportunistic infection . Overthecounter medication alternative therapy vitamins herb . Antibiotics clinically indicate . Steroids &lt; 21 day acute problem . Antipyretics , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , appropriate medication . Concurrent Treatment : Allowed : Radiation therapy cutaneous Kaposi 's sarcoma . Acupuncture . Patients must : Documented HIV infection . CD4 count &lt; = 50 cells/mm3 . Either prior nucleoside therapy OR history prior nucleoside therapy absence highgrade intolerance . Life expectancy least 6 month . Consent parent guardian &lt; 18 year age . Normal chest xray baseline within 6 month prior study entry absence new pulmonary cardiac symptom ( per 12/28/94 amendment ) . NOTE : Patients withdraw protocol ACTG 193 therapy prior activation ACTG 193A eligible . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Abnormal baseline chest xray . New pulmonary cardiac symptom . Psychological emotional problem sufficient prevent compliance study medication . Concurrent Medication : Excluded : Systemic chemotherapy malignancy . Acute induction therapy opportunistic infection . Antiretroviral drug study drug . Biological response modifier . Erythromycin , phenytoin , phenobarbital , warfarin , coumadin . Patients follow prior condition exclude : History recurrent grade 3 great toxicity AZT , ddI , ddC two occasion . Evidence active pulmonary disease within 6 month prior study entry . History grade 3 bad peripheral neuropathy . History acute chronic pancreatitis . Prior Medication : Excluded : Prior nevirapine . Excluded within 7 day prior study entry : Acute therapy opportunistic infection ( maintenance therapy permit ) . Acute systemic therapy nonopportunistic infection medical condition . Antiretroviral drug AZT , ddI , ddC . Biological response modifier . d4T therapy . Nucleosides use study . Antibiotics contain clavulanate potassium . Prior Treatment : Excluded : More 4 unit blood 30day period . Active alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>